Table 1.
Patients characteristics.
| Phase I | Phase II | Total (N = 38) | ||
|---|---|---|---|---|
| Ibrutinib 420 mg + Pembrolizumab (N = 4) | Ibrutinib 560 mg + Pembrolizumab (N = 3) | Ibrutinib 560 mg + Pembrolizumab (N = 31) | ||
| Median age (range) | 62 (50–67) | 49 (47–58) | 59 (24–73) | 59 (24–73) |
| Gender | ||||
| Male | 4 (100%) | 2 (66.7%) | 16 (51.6%) | 22 (57.9%) |
| Female | 0 | 1 (33.3%) | 15 (48.4%) | 16 (42.1%) |
| Race | ||||
| White | 4 (100%) | 3 (100%) | 23 (74.2%) | 30 (78.9%) |
| Hispanic | 0 | 0 | 1 (3.2%) | 1 (2.6%) |
| Blacks | 0 | 0 | 5 (16.1%) | 5 (13.2%) |
| Asian | 0 | 0 | 1 (3.2%) | 1 (2.6%) |
| Unknown | 0 | 0 | 1 (3.2%) | 1 (2.6%) |
| ECOG | ||||
| 0 | 2 (50%) | 3 (100%) | 11 (35.5%) | 16 (42.1%) |
| 1 | 2 (50%) | 0 | 20 (64.5%) | 22 (57.9%) |
| Site of primary tumour | ||||
| Right | 1 (25%) | 0 | 8 (25.8%) | 9 (23.7%) |
| Left | 3 (75%) | 3 (100%) | 23 (74.2%) | 29 (76.3%) |
| Previous chemotherapy | ||||
| 1 line | 0 | 0 | 3 (9.7%) | 3 (7.9%) |
| 2 lines | 1 (25%) | 0 | 9 (29%) | 10 (26.3%) |
| ≥3 lines | 3 (75%) | 3 (100%) | 19 (61.3%) | 25 (65.8%) |
| Site of metastasis | ||||
| Liver | 3 (75%) | 1 (33.3%) | 23 (74.2%) | 27 (71.1%) |
| Lung | 4 (100%) | 2 (66.7%) | 20 (64.5%) | 26 (68.4%) |
| Lymph node | 2 (50%) | 3 (100%) | 19 (61.3%) | 22 (57.9%) |
| Peritoneum | 2 (50%) | 1 (33.3%) | 11 (35.5%) | 14 (36.8%) |
| KRAS/NRAS | ||||
| Wild type | 1 (25%) | 2 (66.7%) | 16 (51.6%) | 19 (50%) |
| Mutant | 3 (75%) | 1 (33.3%) | 15 (48.4%) | 19 (50%) |